Geoffrey Ginsburg, MD, PhD, the director of the Duke Center for Applied Genomics & Precision Medicine and a Duke Cancer Institute member, has joined the inaugural Scientific Advisory Board of the Brotman Baty Institute for Precision Medicine (BBI).
Ginsburg is one of five leaders in genomics and precision medicine joining the board, which also includes Richard Lifton, MD, PhD, President of Rockefeller University; Nancy Cox, PhD, the director of the Vanderbilt Genetics Institute; Sekar Kathiresan, MD, the director of the Center for Genomic Medicine MGH/Broad Institute; and George Church, PhD, professor of genetics at Harvard University.
The board, according to an August press release by the institute, will be charged with helping to “shape the scientific agenda of the BBI, including laying the foundations for a human cell atlas, cataloging the consequences of all possible mutations in medically relevant genes and making transformative impacts on biomedical research to dramatically improve patient outcomes.”
Ginsburg’s areas of focus include the study of novel paradigms for developing and translating genomic information into medical practice, and the integration of patient-specific genetic information into practical health care.
The Brotman Baty Institute was co-founded by University of Washington Medicine, The Fred Hutchinson Cancer Research Center, and Seattle Children’s to accelerate both the basic sciences of precision medicine and the delivery of benefits to patients.